EMILY CUNNINGHAM: Open Payments
NPI 1326815291 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,349 in 69 payments from 23 companies in 2025. Trend: 2023 $0 · 2024 $1,414 · 2025 $1,349
Food & beverage: $1,349
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $184 |
| Novo Nordisk Inc | 9 | $161 |
| ABBVIE INC. | 8 | $137 |
| Sumitomo Pharma America, Inc. | 4 | $99 |
| Exact Sciences Corporation | 4 | $87 |
| PFIZER INC. | 4 | $75 |
| Lilly USA, LLC | 4 | $71 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| GlaxoSmithKline, LLC. | 3 | $59 |
Products named: FARXIGA, GEMTESA, VRAYLAR, REXULTI, Kerendia, AIRSUPRA, SHINGRIX, Wegovy.
Industry payments across SC — which companies pay providers there.
